[1]
|
Porsteinsson, A.P., Isaacson, R.S., Knox, S., Sabbagh, M.N. and Rubino, I. (2021) Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. The Journal of Prevention of Alzheimer’s Disease, 8, 371-386. https://doi.org/10.14283/jpad.2021.23
|
[2]
|
(2023) 2023 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 19, 1598-1695.
|
[3]
|
王荫华, 纪勇. 世界阿尔茨海默病发展现状[J]. 中国现代神经疾病杂志, 2015, 15(7): 507-511.
|
[4]
|
黄丽, 徐英. 阿尔兹海默病患者经济负担的研究进展[J]. 成都医学院学报, 2021, 16(6): 805-808.
|
[5]
|
Breijyeh, Z. and Karaman, R. (2020) Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25, Article No. 5789. https://doi.org/10.3390/molecules25245789
|
[6]
|
Zhang, X.X., Tian, Y., Wang, Z.T., et al. (2021) The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. The Journal of Prevention of Alzheimer’s Disease, 8, 313-321.
|
[7]
|
刘伟, 孙彦. β-淀粉样蛋白的聚集及其调控[J]. 化工学报, 2022, 73(6): 2381-2396.
|
[8]
|
Madhu, P. and Mukhopadhyay, S. (2021) Distinct Types of Amyloid-β Oligomers Displaying Diverse Neurotoxicity Mechanisms in Alzheimer’s Disease. Journal of Cellular Biochemistry, 122, 1594-1608. https://doi.org/10.1002/jcb.30141
|
[9]
|
Jeremic, D., Jiménez-Díaz, L. and Navarro-López, J.D. (2021) Past, Present and Future of Therapeutic Strategies against Amyloid-β Peptides in Alzheimer’s Disease: A Systematic Review. Ageing Research Reviews, 72, Article ID: 101496. https://doi.org/10.1016/j.arr.2021.101496
|
[10]
|
Farias, G., Cornejo, A., Jimenez, J., Guzman, L. and B. Maccioni, R. (2011) Mechanisms of Tau Self-Aggregation and Neurotoxicity. Current Alzheimer Research, 8, 608-614. https://doi.org/10.2174/156720511796717258
|
[11]
|
Johnson, G.V.W. and Stoothoff, W.H. (2004) Tau Phosphorylation in Neuronal Cell Function and Dysfunction. Journal of Cell Science, 117, 5721-5729. https://doi.org/10.1242/jcs.01558
|
[12]
|
王金春, 刘慧影, 曹云鹏. Tau蛋白与阿尔茨海默病[J]. 中国组织工程研究, 2020, 24(17): 2775-2781.
|
[13]
|
Gao, Y., Tan, L., Yu, J. and Tan, L. (2018) Tau in Alzheimer’s Disease: Mechanisms and Therapeutic Strategies. Current Alzheimer Research, 15, 283-300. https://doi.org/10.2174/1567205014666170417111859
|
[14]
|
陈付艳, 谭乔芮. 线粒体在阿尔兹海默症发病机制中的作用研究进展[J]. 医药前沿, 2019, 9(28): 5-7.
|
[15]
|
Desler, C., Lillenes, M.S., Tønjum, T. and Rasmussen, L.J. (2019) The Role of Mitochondrial Dysfunction in the Progression of Alzheimer’s Disease. Current Medicinal Chemistry, 25, 5578-5587. https://doi.org/10.2174/0929867324666170616110111
|
[16]
|
刘兴博. 阿尔茨海默病与氧化应激的研究进展[J]. 母婴世界, 2018(23): 339.
|
[17]
|
Bai, R., Guo, J., Ye, X., Xie, Y. and Xie, T. (2022) Oxidative Stress: The Core Pathogenesis and Mechanism of Alzheimer’s Disease. Ageing Research Reviews, 77, Article ID: 101619. https://doi.org/10.1016/j.arr.2022.101619
|
[18]
|
Chen, Z. and Zhong, C. (2014) Oxidative Stress in Alzheimer’s Disease. Neuroscience Bulletin, 30, 271-281. https://doi.org/10.1007/s12264-013-1423-y
|
[19]
|
Jaber, V.R., Zhao, Y., Sharfman, N.M., Li, W. and Lukiw, W.J. (2019) Addressing Alzheimer’s Disease (AD) Neuropathology Using Anti-Microrna (AM) Strategies. Molecular Neurobiology, 56, 8101-8108. https://doi.org/10.1007/s12035-019-1632-0
|
[20]
|
Wilcock, D.M. (2013) Neuroinflammatory Phenotypes and Their Roles in Alzheimer’s Disease. Neurodegenerative Diseases, 13, 183-185. https://doi.org/10.1159/000354228
|
[21]
|
Wang, S. and Colonna, M. (2019) Microglia in Alzheimer’s Disease: A Target for Immunotherapy. Journal of Leukocyte Biology, 106, 219-227. https://doi.org/10.1002/jlb.mr0818-319r
|
[22]
|
Sarlus, H. and Heneka, M.T. (2017) Microglia in Alzheimer’s Disease. Journal of Clinical Investigation, 127, 3240-3249. https://doi.org/10.1172/jci90606
|
[23]
|
宋博雅. 阿尔兹海默症发病机制的研究进展[J]. 西安文理学院学报(自然科学版), 2020, 23(4): 77-79, 92.
|
[24]
|
Wang, M., Zhang, H., Liang, J., Huang, J. and Chen, N. (2023) Exercise Suppresses Neuroinflammation for Alleviating Alzheimer’s Disease. Journal of Neuroinflammation, 20, Article No. 76. https://doi.org/10.1186/s12974-023-02753-6
|
[25]
|
Fakhoury, M. (2018) Microglia and Astrocytes in Alzheimer’s Disease: Implications for Therapy. Current Neuropharmacology, 16, 508-518. https://doi.org/10.2174/1570159x15666170720095240
|
[26]
|
Kalmankar, N.V., Hari, H., Sowdhamini, R. and Venkatesan, R. (2021) Disulfide-Rich Cyclic Peptides from Clitoria ternatea Protect against β-Amyloid Toxicity and Oxidative Stress in Transgenic Caenorhabditis elegans. Journal of Medicinal Chemistry, 64, 7422-7433. https://doi.org/10.1021/acs.jmedchem.1c00033
|
[27]
|
Birks, J.S. and Harvey, R.J. (2018) Donepezil for Dementia Due to Alzheimer’s Disease. Cochrane Database of Systematic Reviews, 6, CD001190. https://doi.org/10.1002/14651858.cd001190.pub3
|
[28]
|
Marucci, G., Buccioni, M., Ben, D.D., Lambertucci, C., Volpini, R. and Amenta, F. (2021) Efficacy of Acetylcholinesterase Inhibitors in Alzheimer’s Disease. Neuropharmacology, 190, Article ID: 108352. https://doi.org/10.1016/j.neuropharm.2020.108352
|
[29]
|
Tuszynski, M.H., Yang, J.H., Barba, D., U, H., Bakay, R.A.E., Pay, M.M., et al. (2015) Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease. JAMA Neurology, 72, 1139-1147. https://doi.org/10.1001/jamaneurol.2015.1807
|
[30]
|
Katsouri, L., Lim, Y.M., Blondrath, K., Eleftheriadou, I., Lombardero, L., Birch, A.M., et al. (2016) PPARγ-Coactivator-1α Gene Transfer Reduces Neuronal Loss and Amyloid-β Generation by Reducing β-Secretase in an Alzheimer’s Disease Model. Proceedings of the National Academy of Sciences, 113, 12292-12297. https://doi.org/10.1073/pnas.1606171113
|
[31]
|
Rafii, M.S., Tuszynski, M.H., Thomas, R.G., Barba, D., Brewer, J.B., Rissman, R.A., et al. (2018) Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients with Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurology, 75, 834-841. https://doi.org/10.1001/jamaneurol.2018.0233
|
[32]
|
Loera-Valencia, R., Piras, A., Ismail, M.A.M., Manchanda, S., Eyjolfsdottir, H., Saido, T.C., et al. (2018) Targeting Alzheimer’s Disease with Gene and Cell Therapies. Journal of Internal Medicine, 284, 2-36. https://doi.org/10.1111/joim.12759
|
[33]
|
DeMattos, R.B., Lu, J., Tang, Y., Racke, M.M., DeLong, C.A., Tzaferis, J.A., et al. (2012) A Plaque-Specific Antibody Clears Existing β-Amyloid Plaques in Alzheimer’s Disease Mice. Neuron, 76, 908-920. https://doi.org/10.1016/j.neuron.2012.10.029
|
[34]
|
Panza, F., Lozupone, M., Seripa, D. and Imbimbo, B.P. (2019) Amyloid‐β Immunotherapy for Alzheimer Disease: Is It Now a Long Shot? Annals of Neurology, 85, 303-315. https://doi.org/10.1002/ana.25410
|
[35]
|
Schenk, D. (2002) Amyloid-β Immunotherapy for Alzheimer’s Disease: The End of the Beginning. Nature Reviews Neuroscience, 3, 824-828. https://doi.org/10.1038/nrn938
|
[36]
|
van Dyck, C.H. (2018) Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise. Biological Psychiatry, 83, 311-319. https://doi.org/10.1016/j.biopsych.2017.08.010
|
[37]
|
Schneider, L. (2020) A Resurrection of Aducanumab for Alzheimer’s Disease. The Lancet Neurology, 19, 111-112. https://doi.org/10.1016/s1474-4422(19)30480-6
|
[38]
|
Loh, J.S., Mak, W.Q., Tan, L.K.S., Ng, C.X., Chan, H.H., Yeow, S.H., et al. (2024) Microbiota-Gut-Brain Axis and Its Therapeutic Applications in Neurodegenerative Diseases. Signal Transduction and Targeted Therapy, 9, Article No. 37. https://doi.org/10.1038/s41392-024-01743-1
|
[39]
|
Naomi, R., Embong, H., Othman, F., Ghazi, H.F., Maruthey, N. and Bahari, H. (2021) Probiotics for Alzheimer’s Disease: A Systematic Review. Nutrients, 14, Article No. 20. https://doi.org/10.3390/nu14010020
|
[40]
|
Wong, C.B., Kobayashi, Y., et al. (2018) Probiotics for Preventing Cognitive Impairment in Alzheimer’s Disease. In: Evrensel, A. and Ünsalver, B.Ö., Eds., Gut Microbiota-Brain Axis, IntechOpen, 85-104.
|
[41]
|
Distrutti, E., O’Reilly, J., McDonald, C., Cipriani, S., Renga, B., Lynch, M.A., et al. (2014) Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP. PLOS ONE, 9, e106503. https://doi.org/10.1371/journal.pone.0106503
|
[42]
|
Abraham, D., Feher, J., Scuderi, G.L., Szabo, D., Dobolyi, A., Cservenak, M., et al. (2019) Exercise and Probiotics Attenuate the Development of Alzheimer’s Disease in Transgenic Mice: Role of Microbiome. Experimental Gerontology, 115, 122-131. https://doi.org/10.1016/j.exger.2018.12.005
|
[43]
|
Leblhuber, F., Steiner, K., Schuetz, B., Fuchs, D. and Gostner, J.M. (2018) Probiotic Supplementation in Patients with Alzheimer’s Dementia—An Explorative Intervention Study. Current Alzheimer Research, 15, 1106-1113. https://doi.org/10.2174/1389200219666180813144834
|